Tacrolimus Plus Glucocorticoid for Severe Thrombocytopenia in SS
- Conditions
- Sjogren Syndrome With Other Organ Involvement
- Interventions
- Registration Number
- NCT05694130
- Lead Sponsor
- Peking Union Medical College Hospital
- Brief Summary
This 12-week randomized, open-label study evaluates the efficacy and safety of Tacrolimus combined with Glucocorticoid for Sjogren's syndrome patients with severe thrombocytopenia.
- Detailed Description
This study evaluates the efficacy and safety of Tacrolimus combined with Glucocorticoid for the treatment of severe thrombocytopenia in Sjogren's syndrome patients.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 110
- Diagnosis of Sjogren's syndrome according to the 2002 revised American-European Consensus Group (AECG) criteria.
- Baseline platelet counts less than 30×109/L.
- Concomitant other systemic autoimmune diseases.
- Other severe complications of Sjogren's syndrome.
- Abnormal laboratory tests such as: white blood cell count <2.5x10^9/L, hemoglobin <80 g/L, AST/ALT >1.5 ULN, serum creatine > 1.5 mg/dL.
- Received glucocorticoids, immunosuppressants, or biological agents within 3 months.
- Active acute or chronic infections.
- History of malignancy.
- Pregnancy or breastfeeding.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Prednisolone plus Tacrolimus Tacrolimus Oral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks. Oral tacrolimus 1-2mg twice daily for 12 weeks. Prednisolone monotherapy Prednisolone Oral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks. Prednisolone plus Tacrolimus Prednisolone Oral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks. Oral tacrolimus 1-2mg twice daily for 12 weeks.
- Primary Outcome Measures
Name Time Method Complete response rate week 12 Complete response (platelet counts \> 100×10\^9/L) rates at week 12.
- Secondary Outcome Measures
Name Time Method Partial response rate week 4, week 8 and week 12 Partial response (platelet counts 50-100×10\^9/L) rates at week 4, week 8 and week 12
ESSDAI improvement week 12 Change from baseline in ESSDAI (EULAR Sjogren's Syndrome Disease Activity Index) score (0-123, higher is worse) at week 12.
ESSPRI improvement week 12 Change from baseline in ESSPRI (EULAR Sjogren's Syndrome Patient Reported Index) score (0-10, higher is worse) at week 12.
Complete response rate week 4 and week 8 Complete response (platelet counts \> 100×10\^9/L) rates at week 4 and week 8.